Research·October 13, 2026 at 11:37 AM EDT·1 source
Beam suggests it can correct mutation; Pfizer to collaborate with Enodia
BEAM -2.1%PFE
BEAM · last 30 trading days-4.3% since the news
News
What happened
- Beam Therapeutics shared initial data from a Phase 1/2 trial of a base-editing therapy for glycogen storage disease type Ia.
- Pfizer will collaborate with Enodia, although the source provides no further terms or financial details.
Trial phase
Phase 1/2
Why it matters
The update is relevant to healthcare investors and biotechnology professionals tracking early clinical validation of gene-editing platforms and potential pharmaceutical partnerships.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Who is involved
Beam suggests it can correct mutation; Pfizer to collaborate …Beam TherapeuticsBEAMPfizerPFEEnodia
Company
Sources (1)
- Endpoints NewsOct 13Beam suggests it can correct mutation; Pfizer to collaborate with Enodia
Related
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.